Deutsche Bank AG lifted its holdings in shares of Ocular Therapeutix (NASDAQ:OCUL) by 148.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,065 shares of the biopharmaceutical company’s stock after purchasing an additional 29,938 shares during the period. Deutsche Bank AG owned 0.13% of Ocular Therapeutix worth $221,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in the stock. Virtu Financial LLC bought a new stake in shares of Ocular Therapeutix during the 4th quarter valued at about $280,000. BlackRock Inc. boosted its position in shares of Ocular Therapeutix by 0.8% during the 4th quarter. BlackRock Inc. now owns 1,418,577 shares of the biopharmaceutical company’s stock valued at $6,312,000 after purchasing an additional 11,293 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Ocular Therapeutix by 1.0% during the 4th quarter. Jennison Associates LLC now owns 1,994,768 shares of the biopharmaceutical company’s stock valued at $8,877,000 after purchasing an additional 20,132 shares in the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in shares of Ocular Therapeutix during the 3rd quarter valued at about $245,000. Institutional investors own 54.80% of the company’s stock.
Ocular Therapeutix opened at $6.89 on Tuesday, MarketBeat Ratings reports. Ocular Therapeutix has a fifty-two week low of $3.30 and a fifty-two week high of $11.79. The company has a debt-to-equity ratio of 0.22, a quick ratio of 4.89 and a current ratio of 4.90. The company has a market cap of $258.35 million, a P/E ratio of -3.13 and a beta of 1.25.
Ocular Therapeutix (NASDAQ:OCUL) last posted its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Ocular Therapeutix had a negative return on equity of 153.53% and a negative net margin of 3,418.79%. The firm had revenue of $0.34 million for the quarter. equities research analysts forecast that Ocular Therapeutix will post -1.91 earnings per share for the current year.
Several equities research analysts recently commented on the company. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Ocular Therapeutix in a research report on Friday, March 9th. Cantor Fitzgerald set a $22.00 target price on Ocular Therapeutix and gave the company a “buy” rating in a research report on Tuesday, May 8th. Zacks Investment Research lowered Ocular Therapeutix from a “buy” rating to a “sell” rating in a research report on Saturday, May 12th. BTIG Research restated a “buy” rating on shares of Ocular Therapeutix in a research report on Sunday, March 11th. Finally, ValuEngine lowered Ocular Therapeutix from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $11.70.
Ocular Therapeutix Profile
Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. Its lead product candidates include DEXTENZA (dexamethasone insert) for the treatment of post-surgical ocular pain and inflammation, allergic conjunctivitis, and dry eye diseases; and OTX-TP (travoprost insert) for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.
Want to see what other hedge funds are holding OCUL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ocular Therapeutix (NASDAQ:OCUL).
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.